{"id":"W4206730501","doi":"10.1200/jco.2022.40.4_suppl.427","title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Interim analysis; Tolerability; Interim; Oncology; Cohort; Population; Progression-free survival; Tumor progression; Clinical trial; Gastroenterology; Progressive disease; Phases of clinical research; Surgery; Adverse effect; Cancer; Disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005581934,0.001726139,0.002098382,0.0004808561,0.0003790608,0.001219693,0.0007910451,0.001042459,0.001991618],"category_scores_gemma":[0.002376599,0.0005672295,0.002885952,0.0004104522,0.0006626636,0.0009103323,0.0005092619,0.002210262,0.0007648909],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008446263,"about_ca_system_score_gemma":0.00141102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006425921,"about_ca_topic_score_gemma":0.001429023,"domain_scores_codex":[0.9986374,0.000718208,0.00009854094,0.000162618,0.000142513,0.0002406935],"domain_scores_gemma":[0.998007,0.0004375833,0.0006342012,0.0002763327,0.0001745487,0.0004703354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8295794,0.03184085,0.03709789,0.000639274,0.003612848,0.0003666237,0.0002802607,0.003865208,0.02245065,0.0001759527,0.00563392,0.06445713],"study_design_scores_gemma":[0.3329411,0.5490542,0.0940869,0.0000842701,0.003839943,0.001107693,0.0001538407,0.002709265,0.01071253,0.0002450419,0.004967256,0.00009791505],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932274,0.001213639,0.0005013877,0.0002206403,0.00005346951,0.0007844747,0.002680916,0.00007299117,0.001244959],"genre_scores_gemma":[0.9835951,0.0006719556,0.001616457,0.0005515187,0.0001294801,0.001504384,0.01046985,0.00003925802,0.001422073],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005581934,"threshold_uncertainty_score":0.02952039,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1625817100748356,"score_gpt":0.4649976609331365,"score_spread":0.302415950858301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}